Literature DB >> 23394403

Potent and selective inhibition of A-to-I RNA editing with 2'-O-methyl/locked nucleic acid-containing antisense oligoribonucleotides.

Rena A Mizrahi1, Nicole T Schirle, Peter A Beal.   

Abstract

ADARs (adenosine deaminases acting on RNA) are RNA editing enzymes that bind double helical RNAs and deaminate select adenosines (A). The product inosine (I) is read during translation as guanosine (G), so such changes can alter codon meaning. ADAR-catalyzed A to I changes occur in coding sequences for several proteins of importance to the nervous system. However, these sites constitute only a very small fraction of known A to I sites in the human transcriptome, and the significance of editing at the vast majority sites is unknown at this time. Site-selective inhibitors of RNA editing are needed to advance our understanding of the function of editing at specific sites. Here we show that 2'-O-methyl/locked nucleic acid (LNA) mixmer antisense oligonucleotides are potent and selective inhibitors of RNA editing on two different target RNAs. These reagents are capable of binding with high affinity to RNA editing substrates and remodeling the secondary structure by a strand-invasion mechanism. The potency observed here for 2'-O-methyl/LNA mixmers suggests this backbone structure is superior to the morpholino backbone structure for inhibition of RNA editing. Finally, we demonstrate antisense inhibition of editing of the mRNA for the DNA repair glycosylase NEIL1 in cultured human cells, providing a new approach to exploring the link between RNA editing and the cellular response to oxidative DNA damage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23394403      PMCID: PMC3631459          DOI: 10.1021/cb300692k

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  50 in total

Review 1.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

Authors:  C Frank Bennett; Eric E Swayze
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

2.  Matching active site and substrate structures for an RNA editing reaction.

Authors:  Subhash Pokharel; Prasanna Jayalath; Olena Maydanovych; Rena A Goodman; Selina C Wang; Dean J Tantillo; Peter A Beal
Journal:  J Am Chem Soc       Date:  2009-08-26       Impact factor: 15.419

3.  Identification and characterization of a human DNA glycosylase for repair of modified bases in oxidatively damaged DNA.

Authors:  Tapas K Hazra; Tadahide Izumi; Istvan Boldogh; Barry Imhoff; Yoke W Kow; Pawel Jaruga; Miral Dizdaroglu; Sankar Mitra
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

4.  Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome.

Authors:  Michael V Morabito; Atheir I Abbas; Jennifer L Hood; Robert A Kesterson; Michelle M Jacobs; David S Kump; David L Hachey; Bryan L Roth; Ronald B Emeson
Journal:  Neurobiol Dis       Date:  2010-04-13       Impact factor: 5.996

5.  Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims.

Authors:  Ilona Gurevich; Hadassah Tamir; Victoria Arango; Andrew J Dwork; J John Mann; Claudia Schmauss
Journal:  Neuron       Date:  2002-04-25       Impact factor: 17.173

Review 6.  Proteome diversification by adenosine to inosine RNA editing.

Authors:  Dieter Pullirsch; Michael F Jantsch
Journal:  RNA Biol       Date:  2010-03-25       Impact factor: 4.652

7.  Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2'-O-methyl G-clamp ribonucleoside analogues.

Authors:  Stephen C Holmes; Andrey A Arzumanov; Michael J Gait
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

8.  Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.

Authors:  Jason H Williams; Rebecca C Schray; Carlyn A Patterson; Semira O Ayitey; Melanie K Tallent; Gordon J Lutz
Journal:  J Neurosci       Date:  2009-06-17       Impact factor: 6.167

9.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution.

Authors:  Sohrab P Shah; Ryan D Morin; Jaswinder Khattra; Leah Prentice; Trevor Pugh; Angela Burleigh; Allen Delaney; Karen Gelmon; Ryan Guliany; Janine Senz; Christian Steidl; Robert A Holt; Steven Jones; Mark Sun; Gillian Leung; Richard Moore; Tesa Severson; Greg A Taylor; Andrew E Teschendorff; Kane Tse; Gulisa Turashvili; Richard Varhol; René L Warren; Peter Watson; Yongjun Zhao; Carlos Caldas; David Huntsman; Martin Hirst; Marco A Marra; Samuel Aparicio
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

10.  A back-up glycosylase in Nth1 knock-out mice is a functional Nei (endonuclease VIII) homologue.

Authors:  Masashi Takao; Shin-Ichiro Kanno; Kumiko Kobayashi; Qiu-Mei Zhang; Shuji Yonei; Gijbertus T J van der Horst; Akira Yasui
Journal:  J Biol Chem       Date:  2002-08-27       Impact factor: 5.157

View more
  11 in total

Review 1.  ADARs, RNA editing and more in hematological malignancies.

Authors:  Phaik Ju Teoh; Mun Yee Koh; Wee Joo Chng
Journal:  Leukemia       Date:  2020-11-02       Impact factor: 11.528

Review 2.  RNA editing-dependent epitranscriptome diversity in cancer stem cells.

Authors:  Qingfei Jiang; Leslie A Crews; Frida Holm; Catriona H M Jamieson
Journal:  Nat Rev Cancer       Date:  2017-04-18       Impact factor: 60.716

Review 3.  ADAR1 and its implications in cancer development and treatment.

Authors:  Allison R Baker; Frank J Slack
Journal:  Trends Genet       Date:  2022-04-19       Impact factor: 11.821

Review 4.  Deciphering the functions and regulation of brain-enriched A-to-I RNA editing.

Authors:  Jin Billy Li; George M Church
Journal:  Nat Neurosci       Date:  2013-10-28       Impact factor: 24.884

5.  Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer.

Authors:  Daryl Jin Tai Tay; Yangyang Song; Boya Peng; Tan Boon Toh; Lissa Hooi; Desiree-Faye Kaixin Toh; HuiQi Hong; Sze Jing Tang; Jian Han; Wei Liang Gan; Tim Hon Man Chan; Manchugondanahalli S Krishna; Kiran M Patil; Manikantha Maraswami; Teck Peng Loh; Yock Young Dan; Lei Zhou; Glenn Kunnath Bonney; Pierce Kah-Hoe Chow; Gang Chen; Edward Kai-Hua Chow; Minh T N Le; Leilei Chen
Journal:  Mol Ther       Date:  2021-05-08       Impact factor: 11.454

Review 6.  To protect and modify double-stranded RNA - the critical roles of ADARs in development, immunity and oncogenesis.

Authors:  Emily A Erdmann; Ananya Mahapatra; Priyanka Mukherjee; Boyoon Yang; Heather A Hundley
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-12-27       Impact factor: 8.250

Review 7.  Functional Impact of RNA editing and ADARs on regulation of gene expression: perspectives from deep sequencing studies.

Authors:  Hsuan Liu; Chung-Pei Ma; Yi-Tung Chen; Scott C Schuyler; Kai-Ping Chang; Bertrand Chin-Ming Tan
Journal:  Cell Biosci       Date:  2014-08-19       Impact factor: 7.133

8.  Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.

Authors:  Burcu Bestas; Pedro M D Moreno; K Emelie M Blomberg; Dara K Mohammad; Amer F Saleh; Tolga Sutlu; Joel Z Nordin; Peter Guterstam; Manuela O Gustafsson; Shabnam Kharazi; Barbara Piątosa; Thomas C Roberts; Mark A Behlke; Matthew J A Wood; Michael J Gait; Karin E Lundin; Samir El Andaloussi; Robert Månsson; Anna Berglöf; Jesper Wengel; C I Edvard Smith
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

9.  Reciprocal regulation of A-to-I RNA editing and the vertebrate nervous system.

Authors:  Andrew C Penn; Ales Balik; Ingo H Greger
Journal:  Front Neurosci       Date:  2013-04-18       Impact factor: 4.677

Review 10.  RNA editing in the forefront of epitranscriptomics and human health.

Authors:  Theodoulakis Christofi; Apostolos Zaravinos
Journal:  J Transl Med       Date:  2019-09-23       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.